Insulin Aspart Sanofi

Insulin Aspart, the active ingredient in Insulin Aspart Sanofi, is a rapid-acting insulin analog presented as an injection solution for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients.

GNH USA supplies Insulin Aspart Sanofi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulin Aspart is a rapid‑acting insulin analog used to manage blood glucose in diabetes mellitus.

Type 1 diabetes mellitus: improves post‑prandial glucose control and reduces hyperglycaemic episodes. Type 2 diabetes mellitus: assists in achieving glycaemic targets when combined with oral antidiabetic agents. Diabetic ketoacidosis (intensive therapy): provides rapid insulin action needed for metabolic stabilization.

Common Side Effects: - Hypoglycaemia: low blood glucose levels, especially if meals are missed or dosing is excessive. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilisation. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections. - Mild nausea or gastrointestinal discomfort.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypoglycaemia leading to seizures or loss of consciousness. - Hypokalemia: low potassium levels, potentially precipitated by rapid glucose shifts. - Acute insulin resistance: unexpected poor glucose response despite appropriate dosing.

Insulin Aspart requires careful monitoring and individualized dosing.

Dose adjustment: modify dose based on blood glucose trends and carbohydrate intake. Hypoglycaemia risk: educate patients on recognising and treating low blood glucose. Renal impairment: monitor renal function as insulin clearance may be reduced. Pregnancy and lactation: use only if benefits outweigh potential risks. Drug interactions: avoid concomitant use with other rapid‑acting insulins without medical supervision. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart may interact with several medicines that affect glucose metabolism.

Major Interactions (Avoid): - Other insulin products: concurrent use can cause severe hypoglycaemia. - Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection. - Alcohol: enhances insulin’s glucose‑lowering effect, increasing hypoglycaemia risk.

Moderate Interactions (Monitor Closely): - Thiazolidinediones: additive glucose‑lowering effect, require dose adjustments. - Diuretics (especially thiazides): may raise blood glucose, necessitating closer monitoring. - ACE inhibitors or ARBs: can potentiate insulin’s effect in some patients, warranting glucose checks.